Ketotifen
Ketotifen
Jump to navigation
Jump to search
| Clinical data | |
|---|---|
| Trade names | Zaditor[1] |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a604033 |
| Pregnancy category |
|
| Routes of administration | Oral (tablets), ophthalmic solution |
| ATC code |
|
| Legal status | |
| Legal status |
|
Pharmacokinetic data | |
| Bioavailability | 60% |
| Protein binding | 75% |
| Metabolism | Hepatic |
| Elimination half-life | 12 hours |
| Identifiers | |
IUPAC name
| |
| CAS Number |
|
PubChem CID |
|
| IUPHAR/BPS |
|
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEBI |
|
| ChEMBL |
|
| ECHA InfoCard | 100.047.348 |
| Chemical and physical data | |
| Formula | C19H19NOS |
| Molar mass | 309.426 g/mol |
| 3D model (JSmol) |
|
SMILES
| |
InChI
| |
.mw-parser-output .nobold{font-weight:normal} (verify) | |
Ketotifen, sold under the brand name Zaditor among others, is a first-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis.[2] In its oral form, it is used to prevent asthma attacks or Anaphylaxis, as well as various mast cell, allergic-type disorders.[3][4][5][6][7]
Contents
1 Medical uses
2 Side effects
3 Pharmacology
4 Society and culture
4.1 Brand names
5 References
6 External links
Medical uses[edit]
Ketotifen relieves and prevents eye itchiness and/or irritation associated with most seasonal allergies. It starts working within minutes after administering the drops. The drug has not been studied in children under three.[2] The mean elimination half life is 12 hours.[8] Besides its anti-histaminic activity, it is also a functional leukotriene antagonist and a phosphodiesterase inhibitor.
"[O]ral ketotifen has been used in patients with asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, chronic urticaria, cold-induced urticaria, cholinergic urticaria, exercise-induced urticaria, [systemic mast cell disease including mastocytosis, MCAS, allergic and nonallergic anaphylaxis, angioedema], and food allergy in Canada, Europe, and Mexico." Now available via prescription at US compounding pharmacies: "For adults and older children with asthma or allergic disease, the recommended dose of ketotifen is 1 mg twice daily." "FDA staff did recommend more extensive evaluations for management of urticaria."[5][6]
The drug may also help relieve irritable bowel syndrome.[9]
Side effects[edit]
Side effects include drowsiness, weight gain, dry mouth, irritability, and increased nosebleeds.[10]
Pharmacology[edit]
Ketotifen is a selective antihistamine – that is, an inverse agonist of the histamine H1 receptor (Ki = 0.166 nM)[11] – and mast cell stabilizer.[12] In addition, ketotifen has weak anticholinergic (Ki = 204 nM for mACh) and antiserotonergic (Ki = 38.9 nM for 5-HT2A) activity.[11][13] However, at the dosages in which it is typically used clinically, both the anticholinergic and antiserotonergic activity of ketotifen are said not to be appreciable.[14]
Society and culture[edit]
Brand names[edit]
Ketotifen is marketed under many brand names worldwide.[15]
References[edit]
^ http://www.webmd.com/drugs/2/drug-17484/zaditor-opht/details[full citation needed]
^ ab Zaditor prescribing information Archived 2011-06-09 at the Wayback Machine. Novartis
^ Sokol, Kristin C.; Amar, Neil K.; Starkey, Jonathan; Grant, J. Andrew (2013). "Ketotifen in the management of chronic urticaria: Resurrection of an old drug". Annals of Allergy, Asthma & Immunology. 111 (6): 433–6. doi:10.1016/j.anai.2013.10.003. PMC 4309375. PMID 24267353..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}
^ Shawky, Rabah M.; Seifeldin, Neveen S. (2015). "The relation between antihistamine medication during early pregnancy & birth defects". Egyptian Journal of Medical Human Genetics. 16 (4): 287–90. doi:10.1016/j.ejmhg.2015.04.003.
^ ab Zuberbier, Torsten (2012). "A Summary of the New International EAACI/GA2LEN/EDF/ WAO Guidelines in Urticaria". World Allergy Organization Journal. 5 (1): S1–S5. doi:10.1186/1939-4551-5-S1-S1.
^ ab Zuberbier, T.; Asero, R.; Bindslev-Jensen, C.; Walter Canonica, G.; Church, M. K.; Giménez-Arnau, A. M.; Grattan, C. E. H.; Kapp, A.; Maurer, M.; Merk, H. F.; Rogala, B.; Saini, S.; Sánchez-Borges, M.; Schmid-Grendelmeier, P.; Schünemann, H.; Staubach, P.; Vena, G. A.; Wedi, B. (2009). "EAACI/GA²LEN/EDF/WAO guideline: Management of urticaria". Allergy. 64 (10): 1427–43. doi:10.1111/j.1398-9995.2009.02178.x. PMID 19772513.
^ Li, Zhenhong; Celestin, Jocelyn (February 23, 2015). Ketotifen: A Role in the Treatment of Idiopathic Anaphylaxis. American Academy of Allergy, Asthma & Immunology Annual Meeting. Houston.
^ Grahnén, A.; Lönnebo, A.; Beck, O.; Eckernäs, S-Å; Dahlström, B.; Lindström, B. (1992). "Pharmacokinetics of ketotiffn after oral administration to healthy male subjects". Biopharmaceutics & Drug Disposition. 13 (4): 255–62. doi:10.1002/bdd.2510130404. PMID 1600111.
^ Klooker, T. K.; Braak, B.; Koopman, K. E.; Welting, O.; Wouters, M. M.; Van Der Heide, S.; Schemann, M.; Bischoff, S. C.; Van Den Wijngaard, R. M.; Boeckxstaens, G. E. (2010). "The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome". Gut. 59 (9): 1213–21. doi:10.1136/gut.2010.213108. PMID 20650926.
^ "Zaditen - MIMS online". www.mims.co.uk.
^ ab Kakiuchi M, Ohashi T, Musoh K, Kawamura K, Morikawa K, Kato H (1997). "Studies on the novel antiallergic agent HSR-609: its penetration into the central nervous system in mice and guinea pigs and its selectivity for the histamine H1-receptor". Jpn. J. Pharmacol. 73 (4): 291–8. PMID 9165365.
^ Thomas L. Lemke; David A. Williams (2008). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1019–. ISBN 978-0-7817-6879-5.
^ V Alagarsamy (16 June 2012). Textbook of Medicinal Chemistry Vol II - E-Book. Elsevier Health Sciences. pp. 38–. ISBN 81-312-3259-X.
^ Jürgen Drews (6 December 2012). Immunopharmacology: Principles and Perspectives. Springer Science & Business Media. pp. 282–. ISBN 978-3-642-75561-3.
^ drugs.com International availability of ketofin Page accessed April 21, 2015
External links[edit]
- Zaditor web site
- Alaway web site
Categories:
- Benzocycloheptathiophenes
- H1 receptor antagonists
- Mast cell stabilizers
- Piperidines
- Serotonin antagonists
(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"1.004","walltime":"1.225","ppvisitednodes":{"value":5972,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":380418,"limit":2097152},"templateargumentsize":{"value":6851,"limit":2097152},"expansiondepth":{"value":14,"limit":40},"expensivefunctioncount":{"value":4,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":37776,"limit":5000000},"entityaccesscount":{"value":3,"limit":400},"timingprofile":["100.00% 875.304 1 -total"," 54.11% 473.657 1 Template:Drugbox"," 38.33% 335.464 1 Template:Infobox"," 32.28% 282.581 1 Template:Reflist"," 19.53% 170.977 20 Template:Navbox"," 17.89% 156.627 7 Template:Cite_journal"," 10.34% 90.467 16 Template:Unbulleted_list"," 7.55% 66.101 1 Template:Serotonin_receptor_modulators"," 6.53% 57.139 1 Template:Full"," 5.56% 48.705 1 Template:Fix"]},"scribunto":{"limitreport-timeusage":{"value":"0.349","limit":"10.000"},"limitreport-memusage":{"value":7108984,"limit":52428800}},"cachereport":{"origin":"mw1336","timestamp":"20181224095554","ttl":1900800,"transientcontent":false}}});});{"@context":"https://schema.org","@type":"Article","name":"Ketotifen","url":"https://en.wikipedia.org/wiki/Ketotifen","sameAs":"http://www.wikidata.org/entity/Q2458673","mainEntity":"http://www.wikidata.org/entity/Q2458673","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https://www.wikimedia.org/static/images/wmf-hor-googpub.png"}},"datePublished":"2005-07-30T16:21:49Z","dateModified":"2018-09-02T09:14:09Z","image":"https://upload.wikimedia.org/wikipedia/commons/6/6f/Ketotifen.svg","headline":"chemical compound"}(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgBackendResponseTime":108,"wgHostname":"mw1272"});});

